Fig. 2

Association between post-diagnostic use (dispensation of ≥ 270 defined daily doses after diagnosis) of statins, compared to no use, and breast cancer-specific survival, Norway 2004–2017, by age, molecular subtype, stage, and use of chemotherapy. Abbreviation Breast cancer (BC), person-years (PY), hazard ratio (HR), confidence interval (CI), oestrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), triple negative breast cancer (TNBC). ^aAdjusted for age at diagnosis, education, marital status, number of children, country of origin, stage, molecular subtype, histology, and post-diagnostic use of concomitant medications (low-dose aspirin, non-aspirin antiplatelets, metformin, non-metformin antidiabetics, non-steroidal anti-inflammatory drugs, beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and diuretics). The stratified estimates are adjusted for all variables except for the specific stratification variable